What is the appropriate tirofiban dosing for a patient with a creatinine clearance of 52 mL/min?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tirofiban Dosing with CrCl 52 mL/min

For a patient with creatinine clearance of 52 mL/min, use standard tirofiban dosing without renal adjustment: 25 mcg/kg IV bolus followed by 0.15 mcg/kg/min maintenance infusion.

Rationale

A CrCl of 52 mL/min falls into the moderate renal impairment range (30-60 mL/min), but the threshold for tirofiban dose reduction is specifically at CrCl <30 mL/min, not at the broader 30-60 mL/min cutoff used for some other medications.

Specific Dosing Algorithm Based on Renal Function

For CrCl ≥30 mL/min (including your patient with CrCl 52):

  • Loading dose: 25 mcg/kg IV bolus (or alternatively 12 mcg/kg if using older regimen)
  • Maintenance infusion: 0.15 mcg/kg/min (or 0.14 mcg/kg/min per some protocols)
  • Duration: Continue for up to 18 hours at physician discretion 1, 2

For CrCl <30 mL/min only:

  • Loading dose: Reduce to 6 mcg/kg (50% reduction) 1
  • Maintenance infusion: Reduce to 0.05 mcg/kg/min (approximately 50% reduction) 1

Key Evidence Supporting This Recommendation

The FDA drug label explicitly states that plasma clearance of tirofiban is decreased about 40% in subjects with CrCl <60 mL/min, but the formal dose adjustment threshold is set at CrCl <30 mL/min, where clearance is reduced by >50% 3. The 2014 AHA/ACC guidelines clearly specify dose reduction only when "CrCl <30 mL/min" 1.

The 2012 ACC/AHA focused update reinforces this, stating to "reduce rate of infusion by 50% in patients with estimated creatinine clearance <30 mL/min" 2. Note the specific threshold of <30, not <60.

Important Clinical Considerations

  • Monitor bleeding risk carefully: While no dose adjustment is required at CrCl 52, patients with any degree of renal impairment have increased bleeding risk with GP IIb/IIIa inhibitors 1

  • Pharmacokinetic context: Research shows that even at CrCl 30-60 mL/min, tirofiban clearance is reduced by approximately 40% 3. However, the therapeutic window and clinical trial data support standard dosing in this range, with dose reduction reserved for more severe impairment

  • Platelet inhibition monitoring: The standard dose achieves >90% platelet aggregation inhibition within 10 minutes with the high-dose bolus regimen 3. In vitro studies suggest patients with moderate renal dysfunction may actually be more sensitive to tirofiban's antiplatelet effects 4, making bleeding vigilance even more critical

  • Avoid common pitfall: Do not confuse tirofiban's CrCl <30 threshold with eptifibatide's CrCl ≤50 threshold for dose reduction. Eptifibatide requires 50% infusion reduction at CrCl ≤50 mL/min, but tirofiban does not 1, 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.